作者 |郑理 来源 | 独角金融 手握北大双学位、港大金融硕士的"80后"前国泰基金经理姜英，管理公募产品4年后突然转身踏入上市 公司治理层。 10月13日，罗欣药业（002793.SZ）公告称，因工作调动原因，韩风生辞去董事会秘书职务，董事会审 议通过决定聘任姜英为公司董事会秘书。姜英在此之前曾在公募机构国泰基金担任基金经理，2024年离 任，如今从基金经理转向上市公司，相当于换了新的"赛道"。 2022年上半年，她开始管理国泰科创板两年定开、国泰中小盘成长，于2024年12月24日卸任，管理时长 超过两年。截至2024年年末，国泰科创板两年定开、国泰中小盘成长的规模分别约为1.49亿元、4.37亿 元人民币。 图源：公告 基金经理如此选择并不出人意料，近几年，公募基金经理的职业选择早已摆脱"单一化"局限，呈现出日 趋多元化的态势。除了跳槽到其他公募外，他们凭借在公募平台积累的投研能力和客户资源，"公奔 私"是不少资深基金经理的主流选择。如今，越来越多的基金经理跳出资管圈，在不同领域寻找新的机 会。 公开信息显示，姜英1987年10月出生，北京大学理学、经济学双学位本科，北京大学管理学硕士及香港 大学金融学 ...

Group 1 - The article discusses the trend of financial professionals, particularly fund managers, transitioning to different roles, such as company secretaries, amid fluctuating fund performance [2] - Jiang Ying has been appointed as the new company secretary of Luoxin Pharmaceutical, succeeding Han Fengsheng, who resigned [2] - Jiang Ying holds dual degrees in Science and Economics from Peking University, as well as a Master's in Management from Peking University and a Master's in Finance from the University of Hong Kong [2] Group 2 - Jiang Ying's previous performance as a fund manager at Guotai Fund was subpar, with all three funds she managed showing losses during her tenure [4] - The funds managed by Jiang Ying include Guotai Science and Technology Innovation Board Two-Year Fixed Opening, which had a return of -12.48%, Guotai Small and Medium Growth with -34.28%, and Guotai Golden Bull Innovative Growth with -7.01% [4] - Despite the losses, the rankings of Guotai Science and Technology Innovation Board Two-Year Fixed Opening and Guotai Golden Bull Innovative Growth were within the top 50% of their respective categories [3] Group 3 - Jiang Ying's predecessor, Han Fengsheng, saw a steady increase in annual salary from 424,100 yuan in 2022 to 845,700 yuan in 2024 [3] - The article raises questions about Jiang Ying's potential income after transitioning from the fund industry to a corporate role [3]

Group 1 - The article discusses the trend of fund managers transitioning to roles as company secretaries in listed companies, indicating a shift beyond asset management [1][4] - Jiang Ying has been appointed as the new company secretary of Luoxin Pharmaceutical, marking a notable case of a fund manager moving into this role [2][3] - Jiang Ying has a strong academic background with dual degrees in Science and Economics from Peking University, and a Master's in Management and Finance from Hong Kong University, but lacks prior experience as a company secretary [3] Group 2 - Luoxin Pharmaceutical reported a revenue of 1.077 billion yuan for the first half of 2025, a year-on-year decrease of 14.45%, while achieving a net profit of 17.695 million yuan, indicating a turnaround from losses in the previous year [4] - The company has faced significant performance fluctuations in recent years, attributed to factors such as the COVID-19 pandemic, impairment provisions, and adjustments in financial liabilities [4] - The trend of hiring former financial professionals as company secretaries has been noted, with examples including Wang Shangbo from Hongtu Innovation Fund and Liu Haoyu from Dongwu Fund, who have transitioned to roles in listed companies [4]

【 导读 】 基金经理 转型 已 不局限在资管领域， 前国泰基金经理被聘为上市药企董秘 中国基金报记者 储是 10月13日， 罗欣药业发布关于聘任董事会秘书的公告， 显示 聘任姜英为董事会秘书。 公告未披露新任董秘姜英的 薪酬 情况， 前任董秘韩风生2024年薪酬为84.57万元 。 资料显示， 姜英 出生于 1987年，为 北京大学理学、经济学双学位本科，北京大学管理学硕 士及香港大学金融学硕士。 姜英 曾主要任职于国金证券资产管理分公司、光大保德信基金担 任分析师，于国泰基金担任分析师、基金经理助理、基金经理，无上市公司董秘工作经验。 | NEW YORK | 2 11 12 11 11 11 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 열매요이 | 代目 | 产品名称 | 特色同盟 | 田原田町 | NEED | 8000 | 年代回报 | 国际网站 | | 工作品 | 506000.01 | 国泰国际娱乐平台官 | 保障局合量 | 2002-02-18 | 2024-12-24 | -12-43% ...